



123003

MORGAN L. FITCH, JR.  
 FRANCIS A. EVEN\*  
 JULIUS TABIN  
 JOHN F. FLANNERY  
 ROBERT B. JONES  
 JAMES J. SCHUMANN  
 JAMES J. HAMILL  
 TIMOTHY E. LEVSTIK  
 JOSEPH E. SHIPLEY  
 KENNETH H. SAMPLES  
 PHILIP T. PETTI  
 JOSEPH T. NABOR  
 STEVEN C. SCHROER  
 RICHARD A. KABA\*  
 KARL R. FINK  
 MARK W. HETZLER  
 TIMOTHY P. MALONEY  
 JAMES P. KRUEGER  
 STEPHEN S. FAVAKEH  
 EDWARD W. GRAY, JR.\*  
 RICHARD E. WAWRZYNIAK  
 STEVEN G. PARMELEE  
 SHERRI N. BLOUNT\*  
 BRUCE R. MANSFIELD  
 KENDREW H. COLTON\*  
 G. PAUL EDGELL\*  
 RICHARD W. SCHUMACHER  
 MICHAEL A. SANZO\*

## FITCH, EVEN, TABIN &amp; FLANNERY

ATTORNEYS AND COUNSELLORS AT LAW

Established in 1859

SUITE 401L - 1801 K STREET, NW  
WASHINGTON, D.C. 20006-1201

TELEPHONE (202) 419-7000

FACSIMILE (202) 419-7007

## ILLINOIS OFFICE

SUITE 1600 - 120 SOUTH LA SALLE STREET, CHICAGO, ILLINOIS 60603-3406

TELEPHONE (312) 577-7000

## CALIFORNIA OFFICE

SUITE 250 - 9276 SCRANTON ROAD, SAN DIEGO, CA 92121-7707

TELEPHONE (858) 552-1311

## COLORADO OFFICE

SUITE 213 - 1942 BROADWAY, BOULDER, COLORADO 80302

TELEPHONE (303) 402 6966

CHRISTOPHER E. GEORGE\*  
 SCOTT J. MENGHINI  
 EDWARD E. CLAIR  
 SANDRA V. SCAVO  
 JON A. BIRMINGHAM  
 RUDY KRATZ  
 RAMON R. HOCH\*  
 JOHN E. LYHUS  
 STEVEN M. FREELAND  
 DONNA E. BECKER  
 SEAN R. O'DOWD  
 MICHAEL G. VRANICAR  
 BRIAN S. CLISE  
 MARTIN R. BADER  
 DEREK L. PRESTIN  
 MARK A. BORSOS  
 DAVID R. JAGLOWSKI  
 W. BRIAN EDGE\*

## PATENT AGENTS

ERIC J. WHITESELL  
 JONATHAN H. BACKENSTOSE  
 LILIA I. SAFONOV

## OF COUNSEL

THOMAS F. LEBENS  
 GEORGE W. SPELLMIRE, JR.  
 LISA M. SOMMER

December 30, 2003

Commissioner of Patents  
 U.S. Patent and Trademark Office  
 2011 South Clark Place  
 Customer Window, MS Patent Application  
 Crystal Plaza Two, Lobby, Room 1B03  
 Arlington, VA 22202

Re: Continuation Patent Application  
 (Continuation of U.S. 09/254,227)  
 Appl. No.: to be assigned  
 Filed: herewith  
 For: **Novel G Protein-Coupled Receptor**  
 Inventor(s): Ahmad, *et al.*  
 Atty. Dkt.: 7567/80958

Sir:

The following documents are being forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. A copy of application no. 09/254,227, as filed in the U.S. Patent and Trademark Office on March 3, 1999, comprising:

a title page naming Shen Shi-Hsiang, Sultan Ahmad,  
 Yves Fortin, Denis Banville, Dajan Odonnell and  
 Paola Lembo as inventors (unnumbered),  
 62 pages of specification (numbered as pages 1-62),  
 5 pages of claims (numbered as pages 63-67),  
 a one page abstract (numbered as page 68), and  
 6 sheets of formal Drawings (labeled as Fig. 1-Fig.4B);



123003

\*ADMITTED TO D.C. BAR; D.C. PRACTICE OF  
 ALL OTHERS LIMITED TO FEDERAL COURTS  
 AND AGENCIES

2. A copy of the Declaration (37 C.F.R. § 1.63) and Power of Attorney executed by the inventors and filed in the parent application (5 pages);
3. Preliminary Amendment (3 pages);
4. A copy of the recorded Assignment to Astra Pharma Inc. executed by the inventors and filed in the parent application (6 pages);
5. A copy of the Merger document assigning rights from Astra Pharma Inc. to AstraZeneca Canada Inc. filed in the parent application (8 pages);
6. A copy of the Assignment from AstraZeneca Canada Inc. to the National Research Council of Canada filed in the parent application (4 pages);
7. General Authorization for Petition for Extension of Time Under 37 C.F.R. § 1.136(a)(3) (1 page);
8. General Authorization to Charge Deposit Account (1 page);
9. Information Disclosure Statement (3 pages);
10. List of References Cited by Applicant (3 pages); and
11. Two (2) return postcards.

This application is a continuation of U.S. application no. 09/254,227, filed on March 3, 1999. The '227 application represents U.S. national stage of international application PCT/SE98/02348, which had an international filing date of December 16, 1998, and which claims priority to Swedish application no. 9704836-7, filed on December 22, 1997.

The entire disclosure of the prior application, from which an oath or declaration is being supplied herewith in copy form, is considered a part of the disclosure of the accompanying continuation application and is hereby incorporated by reference.

In accordance with the requirements of 37 C.F.R. § 1.53(b), the present continuation application is being filed under the conditions specified in 35 U.S.C. § 120. The inventors named on this continuation application are the same as the inventors named on the parent, and the application is being filed before the patenting, or abandonment of, or termination of proceedings of the parent application (09/254,227).

We are submitting an Information Disclosure Statement which cites references originally submitted in connection with the parent application, U.S. 09/254,227. The present application relies upon 09/254,227 for priority under 35 U.S.C. § 120. Thus, in accordance with 37 C.F.R. § 1.98(d), copies of the listed references are not being submitted. If, for any reason, the Examiner cannot locate a listed reference, Applicants will be happy to submit a copy as a courtesy.

A separate written request under 37 C.F.R. §1.136(a)(3), which is a general authorization to treat any concurrent or future reply requiring a petition for an extension of time under 37 C.F.R. §1.136(a) for its timely submission as incorporating a petition for an extension of time for the appropriate length of time, is enclosed.

A separate written request, which is a general authorization to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, is enclosed.

#### **Fee Calculation**

Applicants calculate the filing fee is as follows:

	<b>Total</b>		<b>No. Extra</b>	<b>Rate</b>	<b>Fee</b>
<b>Basic Filing Fee</b>					<b>770.00</b>
<b>Total Claims Fee</b>	<b>82</b>	<b>20=</b>	<b>62</b>	<b>\$ 18.00</b>	<b>1,116.00</b>
<b>Independent Claims Fee</b>	<b>15</b>	<b>3 =</b>	<b>12</b>	<b>\$ 86.00</b>	<b>1,032.00</b>
<b>Multiple Dependent Claims Fee</b>				<b>\$ 290.00</b>	<b>290.00</b>
<b>TOTAL FEES DUE</b>					<b>\$ 3,208.00</b>

**The application is being filed under 37 C.F.R. § 1.53 without the filing fee.**

**Correspondence in this case should be directed to:**

**Michael A. Sanzo  
Fitch, Even, Tabin & Flannery  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013  
Fax: (202) 419-7007**

Commissioner of Patents  
December 30, 2003  
Page 4

It is respectfully requested that the enclosed postpaid postcards be stamped with the serial number and the date the enclosed documents are received by the PTO and that they be returned as soon as possible.

Respectfully requested,

FITCH, EVEN, TABIN & FLANNERY

A handwritten signature in black ink that reads "Michael A. Sanzo". The signature is written in a cursive, flowing style.

Michael A. Sanzo  
Attorney for Applicants  
Registration No. 36,912

MAS:ct  
Enclosures

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:


Ahmad, *et al.*

(Cont. of Appl. No.: 09/254,227)

Filed: herewith

Appl. No.: to be assigned

For: **Novel G Protein-Coupled Receptor**



Art Unit: to be assigned  
(1646 in parent case)

Examiner: to be assigned  
(J. Murphy in parent case)

Atty. Dkt.: 7567/80958

**General Authorization for Petition for  
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

Applicants hereby request under 37 C.F.R. § 1.136(a)(3) by this general authorization that any concurrent or future reply submitted by Applicants to the United States Patent and Trademark Office for the above-identified patent application requiring a petition for an extension of time under § 1.136(a) for its timely submission be treated as incorporating therein a petition for an extension of time for the appropriate length of time.

If Applicants do not timely pay for any extension fee(s) pursuant to 37 C.F.R. § 1.136(a) which may become due for this application under 37 C.F.R. § 1.17 by check, the Director is hereby authorized to charge such fee(s), and any additional fees which may be required in this application under 37 C.F.R. §§ 1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7567/80958.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo

Michael A. Sanzo  
Reg. No. 36,912  
Attorney for Applicants

Date December 30, 2003  
1801 K Street, N.W., Suite 401L  
Washington, DC 20006-1201  
Phone: (202) 419-7013

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of:

Ahmad, *et al.*

(Cont. of Appl. No.: 09/254,227)

Filed: herewith

Appl. No.: to be assigned

For: **Novel G Protein-Coupled Receptor**



Art Unit: to be assigned  
(1646 in parent case)

Examiner: to be assigned  
(J. Murphy in parent case)

Atty. Dkt.: 7567/80958

**General Authorization to Charge Deposit Account**

Commissioner of Patents  
U.S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, **MS Patent Application**  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, VA 22202

Sir:

The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. §§1.16-1.17 during its entire pendency, or credit any overpayment, to Deposit Account No. 06-1135 under Order No. 7567/80958.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By Michael A. Sanzo

Michael A. Sanzo

Reg. No. 36,912

Attorney for Applicants

Date December 30, 2003

1801 K Street, N.W., Suite 401L

Washington, DC 20006-1201

Phone: (202) 419-7013